Increased epidermal growth factor receptor level in breast cancer cells treated by 1,25-dihydroxyvitamin D3

Molecular pathways involved in the anti‐apoptotic effect of 1,25‐dihydroxyvitamin D3 in primary human keratinocytes

“…with the EGFR and the IGFR signaling systems in different cell types [Falette et al, 1989;Boisseau-Garsaud et al, 1996;GarachJehoshua et al, 1999;Xie et al, 1999;Akutsu et al, 2001;Kveiborg et al, 2001;Sprenger et al, 2001;Gonzalez et al, 2002]. Although less likely, we can not totally exclude from our results that the inhibition of 1,25(OH) 2 D 3 -mediated activation of Akt and ERK by actinomycin D and cycloheximide results from an inhibition of the biosynthesis of components of the PI-3K/Akt and the MEK/ERK pathways, rather than from an inhibition of the 1,25(OH) 2 D 3 effect.…”

Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells

“…In addition, the Vitamin D analog MC903 reduced phosphorylation of EGFR in both SCC13 squamous carcinoma cells and the HaCaT transformed human keratinocyte cell line [46]. While some reports have shown decreased EGFR mRNA and protein levels in human breast cancer cells with 1,25D treatment [47,48], in certain breast cancer cell lines VDR agonists induce EGFR protein expression [48,49]. At present, it is not known whether VDR agonists regulate expression of EGFR protein and/or EGFR kinase activity in human prostate cancer cells.…”

Vitamin D

“…Interestingly, in the human osteosarcoma cell line MG-63, 1,25(OH) 2 D 3 and TGFb synergistically increased IGFBP-3 secretion [347]. Nevertheless, 1,25(OH) 2 D 3 inhibits the growth of both cell lines [350,351]. They upregulate IGFBP-6, which inhibits IGF-II signaling, and type II IGF receptor (IGF-R-II) that also blocks this pathway and accelerates IGF-II degradation [348,349].…”